Literature DB >> 21523806

Plasma glial fibrillary acidic protein levels in children with sickle cell disease.

William J Savage1, Emily Barron-Casella, Zongming Fu, Pratima Dulloor, Lisa Williams, Barbara J Crain, Desiree A White, Jacky M Jennings, Jennifer E Van Eyk, Michael R Debaun, Allen Everett, James F Casella.   

Abstract

To determine if glial fibrillary acidic protein (GFAP) is associated with brain injury in children with sickle cell disease (SCD), we measured plasma GFAP among cross-sectional groups of unselected children with SCD, subsets of children with SCD and normal brain MRI or MRI evidence of cerebral infarct, healthy pediatric controls, and adults with brain injury. Children with SCD had higher plasma GFAP than healthy pediatric controls (mean concentrations 0.14 ± 0.37 vs. 0.07 ± 0.08 ng/mL; P 5 0.003); also, 16.0% (16/100) of children with SCD and cerebral infarct had GFAP elevations above the 95th percentile of healthy pediatric controls (P 5 0.04). Although not statistically significant, children with SCD and cerebral infarct had more elevated GFAP levels than with SCD and no infarct (16/100, 16.0% vs. 14/168, 8.3%; P 5 0.07). Children with SCD and acute brain ischemia had a higher proportion of elevated GFAP than SCD children with normal MRI (3/6, 50% vs.8.3%; P 5 0.01). GFAP was associated with elevated systolic blood pressure in the preceding year and correlated positively with white blood cell count and negatively with age and performance IQ. Plasma GFAP is elevated among children with SCD and may be associated with subclinical brain injury.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21523806      PMCID: PMC3870012          DOI: 10.1002/ajh.21995

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  22 in total

1.  Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.

Authors:  C Hesse; L Rosengren; N Andreasen; P Davidsson; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  Neurosci Lett       Date:  2001-01-19       Impact factor: 3.046

2.  Glial fibrillary acidic protein as a brain injury biomarker in children undergoing extracorporeal membrane oxygenation.

Authors:  Melania M Bembea; William Savage; John J Strouse; Jamie McElrath Schwartz; Ernest Graham; Carol B Thompson; Allen Everett
Journal:  Pediatr Crit Care Med       Date:  2011-09       Impact factor: 3.624

3.  Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study.

Authors:  Edward C Jauch; Christopher Lindsell; Joseph Broderick; Susan C Fagan; Barbara C Tilley; Steven R Levine
Journal:  Stroke       Date:  2006-09-07       Impact factor: 7.914

4.  Design of the silent cerebral infarct transfusion (SIT) trial.

Authors:  James F Casella; Allison A King; Bruce Barton; Desiree A White; Michael J Noetzel; Rebecca N Ichord; Cindy Terrill; Deborah Hirtz; Robert C McKinstry; John J Strouse; Thomas H Howard; Thomas D Coates; Caterina P Minniti; Andrew D Campbell; Bruce A Vendt; Harold Lehmann; Michael R Debaun
Journal:  Pediatr Hematol Oncol       Date:  2010-03       Impact factor: 1.969

5.  Release of glial fibrillary acidic protein is related to the neurovascular status in acute ischemic stroke.

Authors:  M T Wunderlich; C W Wallesch; M Goertler
Journal:  Eur J Neurol       Date:  2006-10       Impact factor: 6.089

6.  Neuropsychologic performance in school-aged children with sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease.

Authors:  W Wang; L Enos; D Gallagher; R Thompson; L Guarini; E Vichinsky; E Wright; R Zimmerman; F D Armstrong
Journal:  J Pediatr       Date:  2001-09       Impact factor: 4.406

7.  Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia.

Authors:  Elliott P Vichinsky; Lynne D Neumayr; Jeffrey I Gold; Michael W Weiner; Randall R Rule; Diana Truran; Jeffrey Kasten; Barry Eggleston; Karen Kesler; Lillian McMahon; Eugene P Orringer; Thomas Harrington; Karen Kalinyak; Laura M De Castro; Abdullah Kutlar; Cynthia J Rutherford; Cage Johnson; Joel David Bessman; Lanetta B Jordan; F Daniel Armstrong
Journal:  JAMA       Date:  2010-05-12       Impact factor: 56.272

8.  Release of glial tissue-specific proteins after acute stroke: A comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein.

Authors:  M Herrmann; P Vos; M T Wunderlich; C H de Bruijn; K J Lamers
Journal:  Stroke       Date:  2000-11       Impact factor: 7.914

9.  Serum glial fibrillary acidic protein is a highly specific biomarker for traumatic brain injury in humans compared with S-100B and neuron-specific enolase.

Authors:  Masahiro Honda; Ryosuke Tsuruta; Tadashi Kaneko; Shunji Kasaoka; Takeshi Yagi; Masaki Todani; Motoki Fujita; Tomonori Izumi; Tsuyoshi Maekawa
Journal:  J Trauma       Date:  2010-07

Review 10.  Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review.

Authors:  Parveen Rashid; Jo Leonardi-Bee; Philip Bath
Journal:  Stroke       Date:  2003-10-23       Impact factor: 7.914

View more
  13 in total

1.  Parent education and biologic factors influence on cognition in sickle cell anemia.

Authors:  Allison A King; John J Strouse; Mark J Rodeghier; Bruce E Compas; James F Casella; Robert C McKinstry; Michael J Noetzel; Charles T Quinn; Rebecca Ichord; Michael M Dowling; J Philip Miller; Michael R Debaun
Journal:  Am J Hematol       Date:  2014-02       Impact factor: 10.047

Review 2.  Proteomic and biomarker studies and neurological complications of pediatric sickle cell disease.

Authors:  Eboni I Lance; James F Casella; Allen D Everett; Emily Barron-Casella
Journal:  Proteomics Clin Appl       Date:  2014-11-06       Impact factor: 3.494

Review 3.  Integrative approaches to treating pain in sickle cell disease: Pre-clinical and clinical evidence.

Authors:  Varun Sagi; Donovan A Argueta; Stacy Kiven; Kalpna Gupta
Journal:  Complement Ther Med       Date:  2020-05-11       Impact factor: 2.446

4.  Glial fibrillary acidic protein as a biomarker for brain injury in neonatal CHD.

Authors:  Stephanie L McKenney; Fahad F Mansouri; Allen D Everett; Ernest M Graham; Irina Burd; Priya Sekar
Journal:  Cardiol Young       Date:  2016-01-20       Impact factor: 1.093

5.  Brain-derived neurotrophic factor levels in pediatric sickle cell disease.

Authors:  Eboni I Lance; Emily Barron-Casella; Allen D Everett; James F Casella
Journal:  Pediatr Blood Cancer       Date:  2019-11-17       Impact factor: 3.167

6.  Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  James F Meschia; Cheryl Bushnell; Bernadette Boden-Albala; Lynne T Braun; Dawn M Bravata; Seemant Chaturvedi; Mark A Creager; Robert H Eckel; Mitchell S V Elkind; Myriam Fornage; Larry B Goldstein; Steven M Greenberg; Susanna E Horvath; Costantino Iadecola; Edward C Jauch; Wesley S Moore; John A Wilson
Journal:  Stroke       Date:  2014-10-28       Impact factor: 7.914

7.  Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas.

Authors:  Hatim Husain; William Savage; Stuart A Grossman; Xiaobu Ye; Peter C Burger; Allen Everett; Chetan Bettegowda; Luis A Diaz; Cherie Blair; Katharine E Romans; Matthias Holdhoff
Journal:  J Neurooncol       Date:  2012-04-11       Impact factor: 4.130

8.  GFAP-BDP as an acute diagnostic marker in traumatic brain injury: results from the prospective transforming research and clinical knowledge in traumatic brain injury study.

Authors:  David O Okonkwo; John K Yue; Ava M Puccio; David M Panczykowski; Tomoo Inoue; Paul J McMahon; Marco D Sorani; Esther L Yuh; Hester F Lingsma; Andrew I R Maas; Alex B Valadka; Geoffrey T Manley
Journal:  J Neurotrauma       Date:  2013-08-01       Impact factor: 5.269

9.  Thrombospondin-1 and L-selectin are associated with silent cerebral infarct in children with sickle cell anaemia.

Authors:  Lisa M Faulcon; Zongming Fu; Pratima Dulloor; Emily Barron-Casella; William Savage; Jacky M Jennings; Jennifer E Van Eyk; Michael Debaun; James F Casella; Allen Everett
Journal:  Br J Haematol       Date:  2013-05-14       Impact factor: 6.998

10.  Acute silent cerebral ischemic events in children with sickle cell anemia.

Authors:  Charles T Quinn; Robert C McKinstry; Michael M Dowling; William S Ball; Michael A Kraut; James F Casella; Nomazulu Dlamini; Rebecca N Ichord; Lori C Jordan; Fenella J Kirkham; Michael J Noetzel; E Steve Roach; John J Strouse; Janet L Kwiatkowski; Deborah Hirtz; Michael R DeBaun
Journal:  JAMA Neurol       Date:  2013-01       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.